EU court rules GSK committed ‘pay-for-delay’ in paroxetine case
The Competition and Markets Authority (CMA) announced the EU Court of Justice agreed that GSK had paid to delay other competitors entering the UK paroxetine generics market.
List view / Grid view
The Competition and Markets Authority (CMA) announced the EU Court of Justice agreed that GSK had paid to delay other competitors entering the UK paroxetine generics market.
Long-term use of some anticholinergic medications are associated with an increased risk of dementia – according to a new study led by the University of East Anglia...
Major international study – comprising largest amount of unpublished data to date – has found that antidepressants are more effective than placebos for short-term treatment of acute depression in adults.